Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial
David E. Kandzari(Piedmont Atlanta Hospital), Denise Reedus, Sidney A. Cohen(University of Pennsylvania), Michael Böhm(Saarland University), Manesh R. Patel(Clinical Research Institute), Kazuomi Kario(Jichi Medical University), David P. Lee, Stuart Pocock(University of London), James W. Choi(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Felix Mahfoud(Saarland University), Susan Steigerwalt, Garrett Pilcher(Medtronic (United States)), Michael A. Weber(SUNY Downstate Health Sciences University), Vasilios Papademetriou, Antony Walton, Raymond R. Townsend(University of Pennsylvania), Roland E. Schmieder, Debbie L. Cohen(University of Pennsylvania), George Dangas, Cara East(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Kiritkumar Patel, Martin Fahy(Medtronic (United States)), Konstantinos Tsioufis(Hippocration General Hospital), Neil Chapman, Philipp Lurz, Thomas Zeller, Janice P. Lea, Jasvindar Singh, Jiro Aoki, Chandan Devireddy, Thomas Weber, David Kandzari(Piedmont Atlanta Hospital), Shukri David(Piedmont Atlanta Hospital), Kengo Tanabe, Sandeep Brar(Medtronic (United States)), Robert B. Wilkins, Andrew S.P. Sharp, Justin E. Davies, Robert Wilensky, Dimitrios Tousoulis(National and Kapodistrian University of Athens), Johanna Contreras, Khaled M. Ziada, Bryan Batson, Joachim Weil
Cited by 775
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k